{"product_id":"can-artificial-intelligence-detect-the-earliest-signs-of-heart-disease-what-a-major-ct-angiography-study-reveals-about-tiny-coronary-plaques","title":"Can Artificial Intelligence Detect the Earliest Signs of Heart Disease? What a Major CT Angiography Study Reveals About Tiny Coronary Plaques","description":"\u003cp\u003eResearchers used an artificial intelligence (AI) tool to detect the tiniest coronary artery plaques — some as small as a fraction of a cubic millimeter — on CT scans of the heart. In a study of 99 patients followed for an average of 3.8 years, they found that 87% of these small plaques were still present at the same location on follow-up scans, and the plaque volume tripled from a median of 6.8 mm³ to 18.9 mm³. This research suggests that AI can reliably identify very early atherosclerosis, and that even extremely small plaques tend to grow over time. The findings open the door to detecting heart disease at its very earliest stages, potentially years before it would cause symptoms.\u003c\/p\u003e\n\n\u003ch1\u003eCan Artificial Intelligence Detect the Earliest Signs of Heart Disease? What a Major CT Angiography Study Reveals About Tiny Coronary Plaques\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters: The Problem of Early Atherosclerosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#results\"\u003eKey Findings: What Happened to the Small Plaques\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#statins\"\u003eThe Role of Statins in Plaque Changes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Research Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: Actionable Advice for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a 99-patient study, AI-QCT detected tiny coronary plaques that human readers often miss.\u003c\/li\u003e\n\u003cli\u003e87% of small plaques persisted at the same location on follow-up scans after about 3.8 years.\u003c\/li\u003e\n\u003cli\u003eMedian plaque volume tripled from 7.1 mm³ to 18.9 mm³ in persistent plaques.\u003c\/li\u003e\n\u003cli\u003eStatins increased plaque calcification, potentially stabilizing soft plaque, but didn't reduce total volume.\u003c\/li\u003e\n\u003cli\u003eNo clinical outcomes were tracked; larger studies are needed to confirm findings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters: The Problem of Early Atherosclerosis\u003c\/h2\u003e\n\n\u003cp\u003eAtherosclerosis — the buildup of fatty plaque inside artery walls — remains the leading cause of cardiovascular death worldwide. Coronary artery disease (CAD) alone affects nearly 200 million people globally and causes more than 9 million deaths each year. It also contributes to approximately 182 million disability-adjusted life years, a measure of healthy life lost to disease and disability.\u003c\/p\u003e\n\n\u003cp\u003eThe news isn't all bad. Prior declines in heart disease deaths had been a public health success story. But those gains are now being threatened by rising rates of obesity and diabetes, which fuel the development of atherosclerosis.\u003c\/p\u003e\n\n\u003cp\u003eOne of the most important discoveries in recent cardiology is that you don't need a severely blocked artery to be at risk. Studies have convincingly shown that \u003cstrong\u003enon-obstructive plaque\u003c\/strong\u003e — plaque that narrows the artery by less than 50% — plays a major role in causing heart attacks and cardiovascular death. On average, patients with non-obstructive CAD have an \u003cstrong\u003e8-fold higher annual event rate\u003c\/strong\u003e compared with patients who have no coronary atherosclerosis at all. Even after adjusting for other risk factors, the hazard ratio for major adverse cardiovascular events ranges from \u003cstrong\u003e1.5 to 7.2\u003c\/strong\u003e when comparing patients with non-obstructive CAD to those with no CAD. This means such patients are anywhere from 50% to over 7 times more likely to experience a heart attack, stroke, or cardiac death.\u003c\/p\u003e\n\n\u003cp\u003eBut a critical question has remained unanswered: do these risks also apply to \u003cem\u003eextremely small\u003c\/em\u003e plaques that are barely visible on imaging? And is there a volume threshold below which risk hasn't yet begun to climb?\u003c\/p\u003e\n\n\u003cp\u003eThere has been a major obstacle to answering these questions. Small, non-calcified plaques are notoriously difficult for human readers to spot on coronary CT angiography (CCTA). They can look almost identical to the soft tissue surrounding the coronary arteries, to other soft tissue structures, or simply to image noise and artifacts. Because of this uncertainty, such tiny plaques are frequently not reported at all.\u003c\/p\u003e\n\n\u003cp\u003eThis is where artificial intelligence enters the picture. A new technology called \u003cstrong\u003eatherosclerosis imaging quantitative computed tomography (AI-QCT)\u003c\/strong\u003e uses machine learning to automatically detect, measure, and characterize plaque throughout the entire coronary tree. In clinical practice, AI-QCT frequently identifies small plaques that human readers miss. But before AI-detected tiny plaques can be used to guide patient care, researchers needed to verify that these detections represent \u003cem\u003ereal\u003c\/em\u003e atherosclerosis and not just software artifacts.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers turned to the \u003cstrong\u003ePARADIGM study\u003c\/strong\u003e (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging), a large international registry that enrolled 2,252 patients from 7 countries and 13 different sites. All participants underwent serial (repeat) CCTA scans for known or suspected coronary artery disease. Patients were enrolled between 2003 and 2015.\u003c\/p\u003e\n\n\u003cp\u003eFor this specific analysis, the research team restricted inclusion to the \u003cstrong\u003efirst 99 patients\u003c\/strong\u003e who underwent CCTA in the cohort. This number was deliberately chosen as a feasibility study, without formal statistical power analysis for any particular outcome. An additional 2 patients were screened but excluded because they did not have any qualifying small plaques.\u003c\/p\u003e\n\n\u003cp\u003eEach patient underwent a baseline scan (CCTA-1) and a follow-up scan (CCTA-2) at least 2 years apart. The scans were performed according to Society of Cardiovascular Computed Tomography guidelines, using 64-detector row or newer scanners with either single- or dual-source technology.\u003c\/p\u003e\n\n\u003cp\u003eThe key innovation was in how the scans were analyzed. A commercially available, \u003cstrong\u003eFDA-cleared AI software\u003c\/strong\u003e (Cleerly Lab, Cleerly, Denver, CO) performed automated analysis using validated convolutional neural network models. The AI system automatically:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSegmented the coronary arteries\u003c\/li\u003e\n  \u003cli\u003eIdentified vessel and lumen contours\u003c\/li\u003e\n  \u003cli\u003eLabeled each coronary segment\u003c\/li\u003e\n  \u003cli\u003eCalculated the percentage of diameter stenosis\u003c\/li\u003e\n  \u003cli\u003eCharacterized plaques by type\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePlaques were classified using Hounsfield unit (HU) density measurements, a scale that quantifies how dense a tissue appears on CT:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCalcified plaque:\u003c\/strong\u003e density greater than 350 HU\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-calcified plaque:\u003c\/strong\u003e density between 30 and 350 HU\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-density non-calcified plaque:\u003c\/strong\u003e density less than 30 HU\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eImportantly, all AI output was verified by a \u003cstrong\u003eLevel III experienced reader\u003c\/strong\u003e — the highest level of CCTA certification — who was blinded to whether each scan was the baseline or follow-up study. This blinding was a critical design element to prevent bias.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSmall plaques were defined as those with a total plaque volume of 0.1 to 50 mm³.\u003c\/strong\u003e For context, 50 mm³ is roughly the size of a small grain of rice.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers examined three specific questions:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eWhat proportion of small plaques identified on the baseline scan were also present at the same location on the follow-up scan? This provided a measure of the software's reliability — plaques that persisted at the same location likely represent true atherosclerosis, while those that vanished could represent either true regression or false-positive detection on the first scan.\u003c\/li\u003e\n  \u003cli\u003eWhat are the characteristics of small plaques, including their calcified, non-calcified, and low-density non-calcified components?\u003c\/li\u003e\n  \u003cli\u003eWhat features are associated with progression of small plaques over time?\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eStatistical analysis was thorough. The team used Student's t-tests and Mann-Whitney U tests for continuous data, Wilcoxon signed-rank tests for paired CCTA characteristics, and Chi-square or Fisher exact tests for categorical data. Logistic regression was used to model which plaques disappeared versus persisted, and linear regression was used to evaluate the impact of statin therapy on plaque volume changes. All tests were two-tailed, with statistical significance defined as p-values below 0.05.\u003c\/p\u003e\n\n\u003ch2 id=\"results\"\u003eKey Findings: What Happened to the Small Plaques\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e99 patients with 502 small plaques\u003c\/strong\u003e were included in the analysis. The participant characteristics paint a picture of a typical middle-aged, at-risk population:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eMedian age: \u003cstrong\u003e61 years\u003c\/strong\u003e (interquartile range 54–67)\u003c\/li\u003e\n  \u003cli\u003eMale gender: \u003cstrong\u003e63%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHypertension: \u003cstrong\u003e55.6%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eCurrent or prior smoking: \u003cstrong\u003e40.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eFamily history of coronary artery disease: \u003cstrong\u003e33.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHypercholesterolemia (high cholesterol): \u003cstrong\u003e31.3%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eDiabetes: \u003cstrong\u003e12.1%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eBody mass index (BMI): median \u003cstrong\u003e25.2 kg\/m²\u003c\/strong\u003e (23.9–27.6)\u003c\/li\u003e\n  \u003cli\u003eStatin use at baseline: \u003cstrong\u003e44.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAt the time of the baseline scan, the median total plaque volume was \u003cstrong\u003e6.8 mm³\u003c\/strong\u003e (interquartile range 3.5–13.9 mm³). The overwhelming majority of this was non-calcified plaque, with a median non-calcified volume of \u003cstrong\u003e6.2 mm³\u003c\/strong\u003e (2.9–12.3 mm³). Calcified plaque volume was essentially zero in most patients.\u003c\/p\u003e\n\n\u003cp\u003eThe mean time between the baseline and follow-up scans was \u003cstrong\u003e3.8 ± 1.6 years\u003c\/strong\u003e. What happened to these tiny plaques over that period is the central finding of the study:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinding #1: 87% of small plaques persisted at the same location.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eOn follow-up imaging, \u003cstrong\u003e437 of 502 plaques (87%)\u003c\/strong\u003e were found at the exact same location as the baseline scan. Among those persistent plaques, \u003cstrong\u003e72% had grown larger\u003c\/strong\u003e, while \u003cstrong\u003e15% had decreased in volume\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinding #2: Small plaque volume tripled over roughly 4 years.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eFor plaques that persisted, the median total plaque volume increased dramatically from \u003cstrong\u003e7.1 mm³\u003c\/strong\u003e (IQR 3.8–15.4 mm³) at baseline to \u003cstrong\u003e18.9 mm³\u003c\/strong\u003e (IQR 8.3–45.2 mm³) on the follow-up scan. That is nearly a \u003cstrong\u003e3-fold increase\u003c\/strong\u003e. The non-calcified component grew from 6.7 mm³ to 13.8 mm³, and calcified plaque volume increased from 0 mm³ to 2.5 mm³. The diameter stenosis (the percentage of the artery blocked) also increased from a median of \u003cstrong\u003e6% to 13%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinding #3: Smaller plaques were less likely to persist.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003ePlaques with a volume under \u003cstrong\u003e2 mm³\u003c\/strong\u003e at baseline persisted in only \u003cstrong\u003e41 of 62 cases (66%)\u003c\/strong\u003e. In contrast, plaques larger than 2 mm³ at baseline persisted in \u003cstrong\u003e395 of 439 cases (90%)\u003c\/strong\u003e. This suggests that extremely tiny plaques are more difficult to distinguish from image noise, though even among these, two-thirds were confirmed to be real atherosclerosis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinding #4: Plaques that \"disappeared\" had distinct characteristics.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe 65 plaques (13%) that were seen on the baseline scan but not on follow-up were significantly different from those that persisted (all p-values \u0026lt; 0.05):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLower total plaque volume:\u003c\/strong\u003e 3.9 mm³ vs. 7.0 mm³\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShorter plaque length:\u003c\/strong\u003e 4.5 mm vs. 6.0 mm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore distal location\u003c\/strong\u003e (further away from the artery opening): 21.8 mm vs. 12.6 mm from the ostium\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eLess likely to have a calcified component\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLess severe diameter stenosis:\u003c\/strong\u003e 3% vs. 6%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, none of the patient-related factors — age, sex, hypertension, smoking history, BMI, family history, hypercholesterolemia, diabetes, or baseline statin use — predicted whether a plaque would persist or disappear. Likewise, scanner-related parameters (vendor, tube current, tube voltage) made no difference. In the multivariable model, only smaller total plaque volume remained independently predictive of a plaque being absent on follow-up.\u003c\/p\u003e\n\n\u003ch2 id=\"statins\"\u003eThe Role of Statins in Plaque Changes\u003c\/h2\u003e\n\n\u003cp\u003eStatin use increased significantly during the study period. At baseline, \u003cstrong\u003e48%\u003c\/strong\u003e of patients were taking statins. By the follow-up scan, that number had risen to \u003cstrong\u003e68%\u003c\/strong\u003e (p \u0026lt; 0.001).\u003c\/p\u003e\n\n\u003cp\u003eAmong 429 small plaques with available statin data, \u003cstrong\u003e145 plaques (33.8%)\u003c\/strong\u003e occurred in patients who were still not taking statins at the time of the follow-up CCTA.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers compared plaque volumes between statin users and non-users at follow-up:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTotal plaque volume:\u003c\/strong\u003e 19.4 mm³ in statin users vs. 18.15 mm³ in non-users — not statistically significant (p = 0.21)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-calcified plaque volume:\u003c\/strong\u003e 12.8 mm³ vs. 14.35 mm³ — not significant (p = 0.68)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCalcified plaque volume:\u003c\/strong\u003e \u003cstrong\u003e3.9 mm³ in statin users vs. 0.2 mm³ in non-users — highly significant (p \u0026lt; 0.001)\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis finding aligns with a well-established biological effect of statins: they stabilize plaque by promoting calcification. A growing body of research shows that statin therapy increases the calcium content of atherosclerotic plaque, which paradoxically makes plaque \u003cem\u003emore\u003c\/em\u003e calcified but \u003cem\u003eless\u003c\/em\u003e dangerous. The fact that statin users showed significantly more calcified plaque volume supports the conclusion that the AI-QCT findings represent true biological atherosclerosis rather than imaging artifacts.\u003c\/p\u003e\n\n\u003cp\u003eIn the regression analysis, statin use at follow-up was significantly associated with changes in calcified plaque volume (p \u0026lt; 0.001) but \u003cstrong\u003enot\u003c\/strong\u003e with changes in total plaque volume (p = 0.30), non-calcified plaque volume (p = 0.70), or low-density non-calcified plaque volume (p = 0.68).\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study carries several important messages for patients and their doctors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, AI can detect real atherosclerosis at remarkably early stages.\u003c\/strong\u003e The fact that 87% of small plaques identified by AI-QCT were confirmed at the same location years later — and often grew substantially — demonstrates that these tiny findings represent genuine disease, not software errors. For patients, this means AI-enhanced CT scans may be able to identify heart disease years or even decades before it would cause symptoms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, very small plaques are not \"harmless\" — they tend to grow.\u003c\/strong\u003e The finding that median plaque volume tripled over an average of 3.8 years is a powerful reminder that atherosclerosis is a progressive disease. A plaque that starts as a 7 mm³ speck can become a 19 mm³ plaque within a few years. While this study did not track clinical outcomes, the broader literature shows that total plaque burden is the main independent predictor of major adverse cardiovascular events.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, statins appear to change the \u003cem\u003ecomposition\u003c\/em\u003e of plaque, even when they don't shrink it.\u003c\/strong\u003e The significantly higher calcified plaque volume in statin users suggests that these medications help convert dangerous soft plaque into more stable calcified plaque. This is consistent with how cardiologists understand statins: they stabilize the \"ticking time bomb\" plaques that are most likely to rupture and cause heart attacks.\u003c\/p\u003e\n\n\u003cp\u003eThe study also highlights a broader trend in preventive cardiology. Prior research in a cohort of nearly 24,000 symptomatic patients referred for cardiac CT found that obstructive coronary artery disease was \u003cstrong\u003enot\u003c\/strong\u003e associated with higher risk than non-obstructive plaque when patients were stratified by total calcified plaque burden. In other words, it's not just about whether an artery is blocked — it's about how much plaque you have throughout your entire coronary tree. Recent data also suggest that even small plaque volumes (\u0026gt;0–250 mm³) increase the 10-year incidence of major adverse cardiovascular events compared with no plaque at all.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Research Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt's important to understand what this study could not show.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe sample size was small.\u003c\/strong\u003e Only 99 patients were included, and this was explicitly designed as a feasibility study without formal statistical power calculation for any specific outcome. Larger studies will be needed to confirm these findings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNo clinical outcomes were tracked.\u003c\/strong\u003e The study measured plaque progression on imaging, not heart attacks, strokes, or deaths. While plaque growth is a well-established surrogate marker for risk, the study does not directly prove that AI-detected small plaques predict future clinical events.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe \"gold standard\" question remains.\u003c\/strong\u003e There is currently no non-invasive gold standard for distinguishing true small plaques from imaging artifacts. The researchers used follow-up CCTA as their reference — reasoning that a plaque present at the same location years later must have been real at baseline. This is a clever approach, but it cannot fully distinguish between true plaque regression and false-positive detection on the baseline scan for the 13% of plaques that disappeared.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHuman reader variability is a known challenge.\u003c\/strong\u003e Previous research cited in this paper found that the kappa coefficient — a statistical measure of reader agreement — was only 0.52 (95% CI 0.49–0.55) for intraobserver agreement and 0.46 (95% CI 0.43–0.49) for interobserver agreement when classifying CCTA as no disease, mild, moderate, or severe. The authors note that agreement would likely be even lower for distinguishing small plaques from no plaque, which underscores the potential value of AI assistance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe study population may not represent all patients.\u003c\/strong\u003e Participants were enrolled from 7 countries but were predominantly middle-aged, and the gender split was 63% male. Results may differ in younger patients, women, or more diverse populations.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: Actionable Advice for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this research and the broader medical literature, here are practical steps patients can consider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your plaque burden, not just your cholesterol numbers.\u003c\/strong\u003e If you have risk factors for heart disease, talk to your doctor about whether a coronary CT angiography or a coronary calcium score is appropriate for you. The total amount of plaque in your coronary arteries is a powerful predictor of risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't dismiss \"mild\" findings.\u003c\/strong\u003e If a CT scan shows non-obstructive plaque or even very small plaques, this is not a clean bill of health. The data are clear: even non-obstructive plaque raises your risk of heart attack compared to having no plaque at all.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider statin therapy if your doctor recommends it.\u003c\/strong\u003e This study reinforces that statins change plaque composition in favorable ways — increasing calcium content and stabilizing dangerous soft plaque — even when they don't dramatically shrink overall plaque volume. The decision to start a statin should be individualized, but patients with documented coronary plaque are often excellent candidates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAddress all modifiable risk factors.\u003c\/strong\u003e In this study, 55.6% of participants had hypertension, 40.4% had a smoking history, and 31.3% had high cholesterol. Controlling blood pressure, quitting smoking, managing cholesterol, maintaining a healthy weight, and controlling diabetes remain the cornerstones of preventing atherosclerosis progression.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about AI-enhanced imaging.\u003c\/strong\u003e If you are undergoing cardiac CT, ask whether AI-based plaque analysis is available. This study suggests that AI software can detect very small plaques that human readers may miss, providing a more complete picture of your cardiovascular risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember that early detection opens the door to prevention.\u003c\/strong\u003e The fact that small plaques can be reliably detected — and that they grow over time — means there is a window of opportunity to intervene with lifestyle changes and medication before plaque becomes extensive.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe takeaway message is hopeful. The ability to detect atherosclerosis at its earliest stages, when a plaque is just a few cubic millimeters in size, represents a genuine advance in preventive cardiology. With tools like AI-QCT, doctors may soon be able to identify patients at risk years earlier than previously possible — and intervene with statins, lifestyle changes, and risk factor control while the disease is still in its infancy.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is AI-QCT and how does it detect small coronary plaques?\u003c\/h3\u003e\n\u003cp\u003eAI-QCT (atherosclerosis imaging quantitative computed tomography) is an FDA-cleared artificial intelligence software that automatically detects, measures, and characterizes plaque throughout the coronary arteries. In a feasibility study of 99 patients, it identified tiny plaques as small as a fraction of a cubic millimeter that human readers often miss. All results were verified by a Level III reader.\u003c\/p\u003e\n\u003ch3\u003eAre very small coronary plaques dangerous or likely to grow?\u003c\/h3\u003e\n\u003cp\u003eIn a study of 99 patients followed for about 3.8 years, 87% of small plaques persisted at the same location, and among persistent plaques, 72% grew larger. Median plaque volume tripled from 7.1 mm³ to 18.9 mm³. This shows that even extremely small plaques tend to progress over time.\u003c\/p\u003e\n\u003ch3\u003eShould I ask my doctor for an AI-enhanced coronary CT scan?\u003c\/h3\u003e\n\u003cp\u003eIf you have risk factors for heart disease, talk to your doctor about whether a coronary CT or calcium score is appropriate. This study suggests AI-based analysis can detect very small plaques that human readers may miss, providing a more complete picture of risk. However, the decision should be individualized.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this study on AI plaque detection?\u003c\/h3\u003e\n\u003cp\u003eThis was a small feasibility study with only 99 patients, and no clinical outcomes such as heart attacks were tracked. The reference standard was follow-up CT, not a gold standard. Results may differ in younger patients, women, or more diverse populations, so larger studies are needed to confirm findings.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in the \u003cem\u003eJournal of Cardiovascular Computed Tomography\u003c\/em\u003e, volume 17 (2023), pages 407–412.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e How early can atherosclerosis be detected by coronary CT angiography - Cleerly James Min\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Rhanderson Cardoso, Andrew D. Choi, Arthur Shiyovich, Stephanie A. Besser, James K. Min, James Earls, Daniele Andreini, Mouaz H. Al-Mallah, Matthew J. Budoff, Filippo Cademartiri, Kavitha Chinnaiyan, Jung Hyun Choi, Eun Ju Chun, Edoardo Conte, Ilan Gottlieb, Martin Hadamitzky, Yong-Jin Kim, Byoung Kwon Lee, Jonathon A. Leipsic, Erica Maffei, Hugo Marques, Pedro de Araújo Gonçalves, Gianluca Pontone, Sang-Eun Lee, Ji Min Sung, Renu Virmani, Habib Samady, Fay Y. Lin, Peter H. Stone, Daniel S. Berman, Jagat Narula, Leslee J. Shaw, Jeroen J. Bax, Hyuk-Jae Chang, and Ron Blankstein\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1016\/j.jcct.2023.08.012\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding and disclosures:\u003c\/strong\u003e Several authors are affiliated with Cleerly Inc., the company that manufactures the AI-QCT software used in this study. The research was an open-access article published under the CC BY-NC-ND license. This patient summary was created by a medical writer and is intended for educational purposes only. It does not constitute medical advice. Patients should discuss their individual cardiovascular risk and treatment options with their healthcare provider.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458366455964,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.tw\/products\/can-artificial-intelligence-detect-the-earliest-signs-of-heart-disease-what-a-major-ct-angiography-study-reveals-about-tiny-coronary-plaques","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}